Who qualifies for lutetium PSMA therapy, why the PSMA PET scan decides it, whether the NHS funds it, and how treatment works, from a UK oncologist.
Key takeaways
- Lutetium PSMA therapy is a targeted treatment for advanced prostate cancer that has spread and stopped responding to hormone treatment. It is given as an injection over four to six cycles.
- A PSMA PET scan decides eligibility. If your cancer does not light up on that scan, the therapy has nothing to lock onto, so it will not be offered.
- It is not a cure. In the pivotal VISION trial, it extended life and delayed the cancer coming back, and it tends to be gentler than chemotherapy.
- On the NHS, it is not routinely funded for this use (NICE decision TA930), so most men in the UK who have it are treated privately or through a trial.
- From February 2026, the therapy can be used earlier in the treatment path for some men, before chemotherapy, which widens who may qualify.
Lutetium PSMA therapy is one of the newer options for men with advanced prostate cancer, and it is a treatment I offer as part of my practice. I am a consultant clinical oncologist based in Guildford and London, and I look after men with prostate cancer, advanced or metastatic prostate cancer and oligometastatic disease. I am also one of a small number of UK oncologists offering lutetium PSMA therapy, and I have been a principal investigator on trials of this kind of treatment.
If you have found your way here, you or someone you love probably has advanced prostate cancer, and you have heard that this therapy might help. You do not need another explanation of how radiation finds a cancer cell. You want to know two things. Am I eligible, and how does it actually work? Those are the questions most pages skirt around, so they are the ones I answer first.
Whether this treatment is right for you is a decision for you and your oncologist, made together and usually with a specialist team. Anyone who has a prostate can develop it, including trans women, non-binary people and some people with intersex variations. Everything here applies to everyone with a prostate.
Who is eligible for lutetium PSMA therapy
Lutetium PSMA therapy is not a first treatment. It is offered when prostate cancer has spread beyond the prostate and has stopped responding to hormone treatment, a stage doctors call metastatic castration-resistant prostate cancer. Put plainly, it is for men whose cancer has already been through some of the standard options and is progressing anyway.
Across the UK and international guidance, the same picture of a typical candidate keeps appearing. You are more likely to be considered if the points below describe your situation.
- Your prostate cancer has spread to other parts of the body, most often the bones or lymph nodes.
- It is no longer controlled by hormone therapy, which is what castration-resistant means.
- You have already had a newer hormone treatment such as enzalutamide or abiraterone.
- You have had chemotherapy, usually a taxane such as docetaxel, or you cannot have it, or you are not well enough for it.
- Blood tests and scans show the cancer is still progressing, and you may have cancer-related bone pain.
One point matters more than all the others, and it is the reason the next section exists. None of the above decides your eligibility on its own. A single scan does.
A recent change worth knowing
Until recently, this therapy was strictly a last-line option, given only after chemotherapy.
In February 2026, the UK medicines regulator, the MHRA, approved it for use earlier in the pathway for some men. That means after a newer hormone treatment but before chemotherapy, where delaying chemotherapy is appropriate.
In practice, more men may now qualify, and it is worth asking your oncologist where you sit in the current pathway.
The PSMA PET scan decides eligibility.
The name of the therapy holds the reason it works. PSMA stands for prostate-specific membrane antigen, a protein that sits in large amounts on the surface of most prostate cancer cells. This is a form of radioligand therapy, which means it uses a carrier molecule that seeks out PSMA and sticks to it, carrying a radioactive payload, lutetium-177, straight to the cancer. The radiation acts over a very short distance, so it damages the cancer while largely sparing healthy tissue.
That targeting only works if your cancer carries enough PSMA to grab hold of. This is checked before treatment with a PSMA PET-CT scan. You are given a small injection of a radioactive tracer that behaves like the treatment but is used for imaging. Where your cancer expresses PSMA, it lights up on the scan.
Why the scan is the gate for lutetium PSMA therapy
If your cancer lights up strongly, the therapy has a target, and you are likely to be offered it. If it does not light up, or lights up only weakly, the treatment has nothing to lock onto. It will not help, so it will not be offered. In the VISION trial, about one in eight men screened were ruled out on their scan. Being otherwise eligible is not enough on its own, because the cancer must produce the PSMA protein for the targeted treatment to work. The scan has the final word.
The same scan doubles as a map. It shows exactly where the cancer has spread, which helps the team plan treatment and judge how you respond later. This pairing of a diagnostic scan with a matched therapy is why the approach is called theranostics. You seek with the scan, then treat with the therapy.
There is a useful overlap here that patients do not always realise. I use PSMA PET imaging to stage disease before planning other treatments too, such as stereotactic radiotherapy and MRI-guided radiotherapy. So the same scan that decides whether lutetium PSMA therapy is right for you can also guide precise radiotherapy to individual spots of cancer, which matters for men with limited spread, or oligometastatic disease.
Lutetium PSMA therapy and the NHS
This is where honest information matters most, because it is the question with the least tidy answer. For the main advanced-prostate-cancer use, lutetium PSMA therapy is not routinely funded on the NHS.
In November 2023, the National Institute for Health and Care Excellence, NICE, which decides what the NHS in England pays for, looked at the therapy and did not recommend it for routine NHS use or the Cancer Drugs Fund. The product it assessed is called lutetium-177 vipivotide tetraxetan. The reasons were cost and gaps in the comparative evidence, not doubt that the treatment works.
So what does that mean in practice? A small number of men access it on the NHS through clinical trials or specific expanded-access arrangements at a few hospitals. Outside those routes, men who have this therapy today are generally treated privately. That is not a comfortable thing to read, but it is the reality, and knowing it early saves you chasing an NHS route that mostly is not there.
The February 2026 approval for earlier use is a licence, not a funding decision, so it does not by itself change the NHS position. Guidance is reviewed over time, so it is always worth asking your oncologist about the current NHS situation and any open trials you could join.
Having lutetium PSMA therapy in the UK
Because this is a specialist treatment, it needs a proper setup behind it, and that is worth understanding before you go looking. A safe lutetium PSMA service brings several things together in one place: a radiopharmacy to prepare the treatment, PSMA PET imaging, a nuclear-medicine team, and an oncologist who can see the therapy in the context of your wider care. Only a handful of UK centres bring all of this together, so availability is limited.
I deliver this pathway for suitable men across the centres where I work, including GenesisCare in Surrey. In practice that means the scan, the multidisciplinary discussion, the treatment and the follow-up are joined up, rather than scattered across places that do not talk to each other. Continuity matters a great deal in a treatment given over months, and it is one of the things I care about most.
Some men also look abroad, where the therapy has been available longer in parts of Europe and Australia. That can be a reasonable option, but treat overseas arrangements with care. Check who oversees your follow-up when you get home, and whether your UK team will coordinate with the centre. Cheaper is not the same as safer, and joined-up care counts for a lot here.
How you get referred
You do not book this therapy the way you would a scan. It runs through a specialist assessment, and the path is broadly the same whether NHS-linked or private.
- Your oncologist reviews your case: your diagnosis, how the cancer has behaved, and the treatments you have already had.
- You have a PSMA PET-CT scan to check whether your cancer expresses enough PSMA to be a target.
- A multidisciplinary team of oncologists, nuclear-medicine doctors, physicists and specialist nurses discusses your scan and agrees whether the therapy is suitable.
- You meet the team at a clinic appointment to talk through what is involved, give consent, and have your questions answered. Treatment does not start at this first appointment, so you have time to decide.
- If you go ahead, your cycles are scheduled, usually every six to eight weeks.
If you are being seen on the NHS and want to explore the private route, ask your current oncologist for a referral and for your scans and records to come with you. A good private centre will want to work alongside your existing team, not around it.
What the treatment day is like
The treatment itself is quick and undramatic. The part that surprises people is what happens straight afterwards, because the medicine is radioactive.
On the day, the team checks you over and goes through consent. A thin tube, a cannula, goes into a vein in your arm or hand, and the lutetium PSMA is given through it. The injection takes only a few minutes. There are no immediate side effects, and you will be asked to drink plenty of water before and after to help your body clear the tracer that the cancer has not taken up.
The isolation period after lutetium PSMA therapy
Because you briefly give off low levels of radiation, you spend a short period on your own after the injection, often around four to six hours, before you go home. Most men have this as a day case, though some centres keep you in overnight. Bring something to fill the wait, such as a book, a tablet or headphones.
Radiation-safety precautions at home
For a short time after each treatment, you will be asked to follow simple steps to limit other people’s exposure to radiation. These are practical, not frightening. They include keeping a sensible distance from young children and pregnant women for a few days, and basic hygiene steps. Your team gives you clear, written instructions for your treatment, and the precautions ease off within days as the radioactivity falls.
How many treatments you need and how they are spaced
A course is usually four to six cycles. The spacing varies a little between centres and protocols, from about every six weeks to every eight, so a full course typically runs over several months.
You are not simply put through all the cycles regardless. Between treatments you have blood tests, and your team checks how you are responding, often with a repeat scan and a PSA blood test. If the therapy is working and you are tolerating it, you continue. If your scans show it is not helping, or side effects are a problem, the plan is reviewed. Roughly half the men in the VISION trial went on to have the optional fifth and sixth cycles, which gives a sense of how individual the course is.
Side effects and how manageable they are
One of the reasons I value this therapy is that it tends to be gentler than chemotherapy. Because a few healthy tissues carry small amounts of PSMA, some side effects are common, but they are usually mild and short-lived.
- Dry mouth and sometimes dry eyes. The salivary glands take up a little of the treatment. This is one of the most common effects.
- Tiredness, often described as more fatigue than usual for a week or so after each cycle.
- Nausea or reduced appetite, usually short-lived and manageable.
- Lower blood counts. The bone marrow can take up some of the radiation, so red cells, white cells or platelets can dip. This is why you have regular blood tests, and occasionally a blood transfusion is needed if counts fall a lot.
If you have already had a lot of chemotherapy or radiotherapy, your bone marrow may be more sensitive, and your team will weigh that up before starting. Less often, there can be mild effects on the kidneys or liver. Your team keeps an eye on all of this, and the point of the follow-up is to catch and manage anything early. Serious problems are uncommon, but always report new or worsening symptoms rather than waiting for the next appointment. These effects are different from the side effects of hormone treatment you may already know, so it helps to keep the two separate in your mind.
What the evidence shows about lutetium PSMA therapy
It is fair to want proof before pinning hopes on a treatment. Here, the evidence is genuinely encouraging, while still being honest about its limits.
The pivotal study is the VISION trial, published in the New England Journal of Medicine in 2021. It tested lutetium PSMA therapy, sometimes written as 177Lu-PSMA, added to standard care against standard care alone, in men whose cancer had already been through hormone treatment and chemotherapy. Adding the therapy extended overall survival to a median of 15.3 months, compared with 11.3 months without it, and it delayed the cancer progressing on scans. An earlier Australian trial, TheraP, compared it against a chemotherapy drug and found it worked at least as well, with fewer severe side effects.
Two things need saying alongside those numbers. First, they are averages from trials. Your own response cannot be promised, and some men respond much better than the median while others respond less. Second, and this is the honest part every patient deserves, this therapy is not a cure. Advanced prostate cancer that has spread cannot currently be cured. What lutetium PSMA therapy can do, for the right man, is control the cancer, ease symptoms and buy good-quality time. That is a meaningful aim, and it is the right one to hold.
Questions worth asking your oncologist
You will get more from your appointment if you go in with the questions that actually shape your decision. These are a good start.
- Based on my PSMA PET scan, am I a good candidate, and how strongly did my cancer show up?
- Given the 2026 change, could I have this before chemotherapy, or is chemotherapy still recommended for me first?
- Is there an NHS trial or expanded-access route I could be considered for?
- What are the realistic goals for me: controlling symptoms, extending life, or both?
- How will we know if it is working, and what happens if it is not?
- How does this option compare with other treatments you offer, such as radiotherapy to individual spots of cancer?
Speak to Dr Carla Perna about your care
Deciding on treatment for advanced prostate cancer is a lot to carry, and you do not have to work it out on your own. I look after men with advanced and metastatic prostate cancer across Guildford and London. I offer lutetium PSMA therapy alongside the full range of radiotherapy, from SABR to MRI-guided treatment, as well as care for oligometastatic disease.
Frequently Asked Questions
Is lutetium PSMA therapy available on the NHS?
Not routinely for advanced prostate cancer. In 2023, NICE, in decision TA930, did not recommend it for routine NHS use or the Cancer Drugs Fund, mainly on cost grounds. A small number of men access it through clinical trials or expanded-access schemes, but most who have it currently pay privately. The February 2026 approval for earlier use is a licence, not a funding decision, so ask your oncologist about the current situation and any open trials.
Who is eligible for lutetium PSMA therapy?
It is for advanced prostate cancer that has spread and stopped responding to hormone therapy, known as metastatic castration-resistant prostate cancer. This is usually after a newer hormone treatment and after chemotherapy, or when chemotherapy is not suitable. From February 2026, it can also be used earlier, before chemotherapy, in some cases. The deciding factor is a PSMA PET scan. Your cancer must show enough PSMA to be a target.
What is a PSMA PET scan and why do I need one first?
It is a scan that shows where your prostate cancer is and whether it carries the PSMA protein the therapy targets. If your cancer lights up, the treatment has something to lock onto, and you are likely to be offered it. If it does not, the therapy will not work for you. That is why the scan decides eligibility before treatment can be planned.
Is lutetium PSMA therapy a cure for prostate cancer?
No. Advanced prostate cancer that has spread cannot currently be cured. For suitable men, lutetium PSMA therapy can control the cancer, ease symptoms and extend life. In the VISION trial, it extended survival by a median of about four months compared with standard care alone, though individual responses vary.
What are the side effects of lutetium PSMA therapy?
The most common are dry mouth, tiredness, nausea or reduced appetite, and a temporary drop in blood counts. They are usually mild and manageable, and the therapy tends to be gentler than chemotherapy. Less often, there can be mild kidney or liver effects. You have regular blood tests so anything can be caught and managed early.
Can I have lutetium PSMA therapy before chemotherapy?
Possibly, since February 2026. The UK regulator approved an earlier use for some men: after a newer hormone treatment and before chemotherapy, where delaying chemotherapy is appropriate. Whether it applies to you depends on your case, so ask your oncologist where you sit in the current treatment pathway.
